The Carle Heart and Vascular Institute is one of the largest cardiovascular institutes in Illinois. Our cardiologists, cardiac surgeons, vascular surgeons and interventional radiologists treat more than 30,000 patients in Illinois, Indiana and the region each year. They offer unparalleled experience in caring for patients with heart and blood vessel diseases.
What does that mean to you as a patient? It means you’ll have access to the area’s largest and most specialized care providers in the state. It means you don’t have to travel to far destinations to receive excellent care.
Have a patient referral? Refer a patient now.
Research is a core mission of Carle Heart and Vascular Institute (HVI). HVI works closely with the Stephen’s Family Clinical Research Institute to offer patients leading-edge therapies through clinical trials. Our physician investigators (cardiologists, cardiac surgeons, vascular surgeons and radiologists) are involved in multiple national and investigator-initiated studies that span the field of pharmacotherapy and interventional devices. Also, HVI is actively involved in translational research activities in collaboration with the Beckman Institute for Advanced Science and Technology.
The Cryo AF Global Registry is a prospective, global, multi-center, observational post-market registry (PMR). The purpose of this study is to evaluate and describe clinical performance and safety data in a broad patient population treated with a commercially available Arctic Front™ Family of Cardiac Cryoablation Catheters (hereafter referred to as "Arctic Front™ Cardiac Cryoablation Catheter System"). The cryoballoon ablation(CBA) procedure will be performed according to routine hospital practice. The study is expected to have a 24 month enrollment period. The follow up period is intended to align with standard practice and subjects will be followed for a minimum of 12 months post-procedure.
The purpose of this registry (“the PERT Registry”) is to gather data on patients diagnosed with pulmonary embolism, treated by the Pulmonary Embolism Response Team (PERT) at each site and beyond for epidemiologic, therapeutic, quality assessment and outcomes research.
The purpose of this study is to determine whether patients undergoing coronary intervention that also require oral anticoagulation, treatment with the COBRA PzF stent plus 14-day dual anti-platelet therapy (DAPT) has higher safety and non-inferior outcomes for thrombo-embolic events than compared with standard FDA-approved drug eluting stent (DES) plus 3 or 6-month DAPT.
With doctors practicing in 80 specialties at locations throughout the region, it’s easy to find the right healthcare team at Carle. Our mission is to serve people through high quality care, medical research and education.
Recognized among the nation’s top hospitals, Carle provides excellent healthcare while continuously improving to meet the needs of our patients.